You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Short report
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

 

Online download statistics by month:

Online download statistics by month: August 2020 to June 2025

AbstractFullPdf
Aug 2020430431220
Sep 2020268268107
Oct 202013513572
Nov 202012111951
Dec 202019219246
Jan 202126426483
Feb 202124424461
Mar 202128828874
Apr 202129029058
May 202121421486
Jun 202116516451
Jul 202114614640
Aug 202114614643
Sep 202115015043
Oct 202118018064
Nov 202116416462
Dec 202113714037
Jan 2022899236
Feb 2022798931
Mar 2022859744
Apr 2022617123
May 2022909818
Jun 2022849122
Jul 2022919220
Aug 202210310434
Sep 2022939428
Oct 20229910136
Nov 2022979737
Dec 202211011013
Jan 202311911933
Feb 202311711712
Mar 202312212835
Apr 2023697021
May 202310210523
Jun 2023777927
Jul 2023656522
Aug 2023797918
Sep 2023575719
Oct 2023616132
Nov 2023676719
Dec 2023515127
Jan 2024444524
Feb 2024798037
Mar 20247777170
Apr 2024676845
May 2024535335
Jun 2024444526
Jul 2024575929
Aug 2024373718
Sep 2024353620
Oct 2024545529
Nov 2024424326
Dec 2024393915
Jan 2025676729
Feb 2025373719
Mar 2025495028
Apr 2025909030
May 2025252520
Jun 2025515113
Total654866262441